Abstract: Diagnostic vehicles, systems, and methods for characterizing a solar collector system are presented herein. The diagnostic vehicle comprises a frame, one or more sensors positioned along the frame, and a control system. The one or more sensors measure and characterize attributes of the solar collector system and/or its environment such as reflectivity of an area of ground around the solar collector system, an angular offset of a drive system of the solar collector system, and/or a degradation of structural components that support photovoltaic panels in the solar collector system. The control system is programmed to move the frame to one or more locations in the solar collector system and control the one or more sensors to acquire measurements at the one or more locations.

Abstract: Systems and methods for dual tilt, ballasted photovoltaic module racking are provided herein. Under one aspect, a system for supporting first and second photovoltaic modules can include first and second elongated stiffeners respectively configured to be coupled to and support the first and second photovoltaic modules. The system also can include first and second feet respectively configured to be coupled to first and second grooves respectively provided within first and second ballasts. The system also can include a first stiffener hinge rotatably coupling the first and second stiffeners to one another, a first foot hinge rotatably coupling the first foot to the first stiffener, and a second foot hinge rotatably coupling the second foot to the second stiffener. At least one of the first stiffener hinge and the first and second foot hinges can include a respective mechanical stop inhibiting rotation of that hinge beyond a respective predetermined angle.

Abstract: Systems and methods for dual tilt, ballasted photovoltaic module racking are provided herein. Under one aspect, a system for supporting first and second photovoltaic modules can include first and second elongated stiffeners respectively configured to be coupled to and support the first and second photovoltaic modules. The system also can include first and second feet respectively configured to be coupled to first and second grooves respectively provided within first and second ballasts. The system also can include a first stiffener hinge rotatably coupling the first and second stiffeners to one another, a first foot hinge rotatably coupling the first foot to the first stiffener, and a second foot hinge rotatably coupling the second foot to the second stiffener. At least one of the first stiffener hinge and the first and second foot hinges can include a respective mechanical stop inhibiting rotation of that hinge beyond a respective predetermined angle.

Abstract: Systems and methods for dual tilt, ballasted photovoltaic module racking are provided herein. Under one aspect, a system for supporting first and second photovoltaic modules can include first and second elongated stiffeners respectively configured to be coupled to and support the first and second photovoltaic modules. The system also can include first and second feet respectively configured to be coupled to first and second grooves respectively provided within first and second ballasts. The system also can include a first stiffener hinge rotatably coupling the first and second stiffeners to one another, a first foot hinge rotatably coupling the first foot to the first stiffener, and a second foot hinge rotatably coupling the second foot to the second stiffener. At least one of the first stiffener hinge and the first and second foot hinges can include a respective mechanical stop inhibiting rotation of that hinge beyond a respective predetermined angle.

Abstract: The present invention relates to methods and formulations directed to the management of Cathepsin G, Cathepsin S, Cathepsin B, Cathepsin L, Butyryl Cholinesterase, Peptidase HIV-1, and NF-kB enzymes comprising the administration of processed Morinda citrifolia based formulations.

Abstract: The present invention features a novel use of processed ingredients from the Indian mulberry plant, and particularly a novel use of one or more processed Morinda citrifolia-based naturaceutical formulations comprising one or more of a processed Morinda citrifolia fruit juice, puree juice, oil or oil extract, dietary fiber, alcohol extract, etc., for inhibiting and preventing the overgrowth of Candida fungus and for treating Candidiasis and its associated symptoms.

Abstract: The present invention is directed to methods of inhibiting Aromatase or Aromatase enzymes that function to convert androgens to estrogens, inhibiting receptors from binding with estrogen, and reducing and/or regulating estrogen production, as well as reducing the amount of estrogen produced within the body and regulating such production. The present invention methods and compositions effectively function to treat estrogen-dependent cancers, and particularly inhibit, destroy, and reverse the effects of estrogen-dependent cancerous tumors through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration.

Abstract: The present invention features a formulation from the Indian mulberry plant (Morinda citrifolia ) comprising Morinda citrifolia fruit juice, Morinda citrifolia oil, quercetin, Morinda citrifolia puree juice and Morinda citrifolia dietary fiber treating Candidiasis.

Abstract: The present invention relates to methods, compositions and their constituents for inhibiting 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), in living organisms. More particularly, the present invention relates to methods and compositions involving the inhibition of 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), using processed Morinda citrifolia L. plant products.

Abstract: This invention relates to a method and composition for providing in various health benefits by administering various bioactive compounds derived from the plant Morinda cirtrifolia to individuals. This invention relates to using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf. More particularly this invention relates to administering one or more of the following: Pyro-phorbide a, Pheophorbide a, Purpin 7, and/or Pheophorbide all which may be derived from Noni leaf extract, Noni leaf juice, and/or Roast leaf. Moreover, the foregoing formulations result in alleviating pain and inflammation.

Abstract: The present invention is directed to methods and formulations for inhibiting Lipoxygenase enzymes that function to biosynthesize or metabolize arachidonic acid into its intermediate Leukotriene constituents, as well as a method and formulation for treating and preventing diseases, including inflammatory diseases, and the symptoms associated with such diseases. The present invention methods and formulations effectively function as such through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration, wherein the processed Morinda citrifolia product may comprise one or more isolated active ingredients.

Abstract: Methods and compositions for inhibiting 5-Lipoxygenase, 15-Lipoxygenase, COX-1, COX-2, Interleukin-l?, Interleukin-6, ?, HLE, and iNOS. Methods and compositions for treating and preventing diseases, including inflammatory diseases and skin cancer. Compositions comprising processed Morinda citrifolia components, some of which include leaf extracts, leaf juice, and/or seed extracts.

Abstract: A method and composition for inhibiting certain enzymes, where such inhibition results in various health benefits is provided. More particularly, a method and composition using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf to inhibit the following: HMG-CoA Reductase; Phosphodiesterases (3 and 4) PDE3 and PDE4; 5-Lipoxygenase (LOX) and 15-LOX; Xanthine Oxidase (XO); Gamma Amino Butyric Acid (GABA) and the growth of the second most common human skin cancer cell line, is provided. Moreover, the foregoing enzymatic inhibitions result in: alleviating pain and inflammation; treating prostate cancers; lowering cholesterol levels; counteracting Diabetes Type II; maintaining the highest possible integrity of cellular interactions in the brain resulting in an undisturbed neural function, (i.e.

Abstract: The present invention relates to methods and formulations directed to the management of various Matrix Metalloproteinases enzymes comprising the administration of processed Morinda citrifolia based formulations.

Abstract: The present invention relates to nutraceutical formulations and methods for use of fetid oil derived from Morinda citrifolia seeds. Research supporting this invention indicates that processed Morinda citrifolia seed products may be used for weight management and health promotion. The present invention is supported by research findings related to the nutritional benefits of fetid oil extracted from the seeds contained within Morinda citrifolia fruit. This oil has been found to include high concentrations of linoleic acid, which is known to increase metabolic rate, help prevent cancer, protect the liver, and help prevent the build up of artery plaque. These observations are consistent with the concept that noni, can positively affect the regulation of excess body weight and promote overall good health.

Abstract: The invention relates to formulations and methods for preventing and/or treating substance abuse, addiction, withdrawal symptoms, and anticipation associated with substance abuse. In particular the invention relates to formulations comprising at least one processed Morinda citrifolia L. product, and methods comprising the administration of at least one processed Morinda citrifolia L product to prevent and/or treat substance abuse, addiction, withdrawal symptoms, and anticipation associated with substance abuse in living organisms. Embodiments of the invention further comprise Morinda citrifolia based nutraceuticals and administration thereof to affect regulation of dopamine levels, inhibition of opioid receptors, inhibition of mu opioid receptors, inhibition of kappa opioid receptors, inhibition of delta opioid receptors, acting as NMDA antagonist, inhibition of sensitization of NMDA receptors, and/or acting as opiate antagonists.

Abstract: The present invention relates to methods and compositions for reactivating Acetylcholinesterase in living organisms using contents from the Morinda citrifolia L. plant. More particularly, the present invention relates to methods and compositions involving the reactivation of Acetylcholinesterase using fruit juice obtained from the Morinda citrifolia L. plant.

Abstract: The present invention is directed to methods of inhibiting Aromatase or Aromatase enzymes that function to convert androgens to estrogens, inhibiting receptors from binding with estrogen, and reducing and/or regulating estrogen production, as well as reducing the amount of estrogen produced within the body and regulating such production. The present invention methods and compositions effectively function to treat estrogen-dependent cancers, and particularly inhibit, destroy, and reverse the effects of of estrogen-dependent cancerous tumors through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration.

Abstract: The present invention relates to weight management utilizing processed Morinda citrifolia products. Research supporting this invention indicates that processed Morinda citrifolia products may be used in weight management. The present invention is supported by research findings that suggest that oral administration of Morinda citrifolia can increase metabolic rate. An increased metabolic rate causes an individual to burn an increased amount of body fat. These observations are consistent with the concept that noni, can positively affect the regulation of excess body weight.

Abstract: The present invention relates to methods and formulations directed to the management of Cathepsin G, Cathepsin S, Cathepsin B, Cathepsin L, Butyryl Cholinesterase, Peptidase HIV-1, and NF-kB enzymes comprising the administration of processed Morinda citrifolia based formulations.